Table 2.
The correlations of KRAS gene expression levels in CTCs with clinicopathological features in patients with CRC.
| Characteristics | Total (29) | Low | High | p-Value |
|---|---|---|---|---|
| Gender | ||||
| Female | 11 (37.9%) | 4 (36.4%) | 7 (63.6%) | 0.313 |
| Male | 18 (62.1%) | 10 (55.6%) | 8 (44.4%) | |
| Age | ||||
| ≤60 years | 9 (31%) | 3 (33.3%) | 6 (66.7%) | 0.276 |
| >60 years | 20(69%) | 11 (55%) | 9 (45%) | |
| Size | ||||
| ≤50 mm | 21 (72.4%) | 8 (38.1%) | 13 (61.9%) | 0.071 |
| >50 mm | 8 (27.6%) | 6 (75.0%) | 2 (25.0%) | |
| Tumour perforation | ||||
| No | 26 (89.7%) | 11 (42.3%) | 15 (57.75%) | 0.029 |
| With perforation | 3 (10.3%) | 3 (100%) | 0 (0.0%) | |
| Site | ||||
| Colon | 16 (55.2%) | 9 (56.3%) | 7 (43.8%) | 0.339 |
| Rectum | 13 (44.8%) | 5 (38.5%) | 8 (61.5%) | |
| Grade | ||||
| Well | 6 (20.7%) | 2 (33.3%) | 4 (66.7%) | 0.082 |
| Moderate | 20 (69.0%) | 9(45.0%) | 11 (55.0%) | |
| Poor | 3 (10.3%) | 3 (100%) | 0 (0.0%) | |
| T stage | ||||
| I or II | 9 (31.0%) | 5 (55.6%) | 4 (44.4%) | 0.599 |
| III or IV | 20 (69.0%) | 9 (45.0%) | 11 (55.0%) | |
| Lymph node status | ||||
| Negative | 18 (62.1%) | 6 (33.3%) | 12 (66.7%) | 0.037 |
| Positive | 11 (37.9%) | 8 (72.7%) | 3 (27.3%) | |
| Distant metastasis | ||||
| Negative | 23 (79.3%) | 9 (39.1%) | 14(60.9%) | 0.046 |
| Positive | 6 (20.7%) | 5 (83.3%) | 1 (16.7%) | |
| Overall stage | ||||
| I or II | 16 (55.2%) | 4 (25.0%) | 12 (75.0%) | 0.004 |
| III or IV | 13 (44.8%) | 10 (76.9%) | 3 (23.1%) | |
| MSI status | ||||
| Stable | 26 (89.7%) | 12 (46.2%) | 14 (53.8%) | 0.498 |
| High | 3 (10.3%) | 2 (66.7%) | 1 (33.3%) | |
| CTC group | ||||
| Low | 16 (55.2%) | 5 (31.3%) | 11 (68.8%) | 0.039 |
| High | 13 (44.8%) | 9 (69.2%) | 4 (30.8%) |